Search

Your search keyword '"Kim, Nam Doo"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Kim, Nam Doo" Remove constraint Author: "Kim, Nam Doo" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
26 results on '"Kim, Nam Doo"'

Search Results

1. Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

2. Data from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

3. Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

4. Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

5. Supplementary Methods from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

6. Supplementary Table S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

7. Supplementary Table S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

8. Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

9. Supplementary Figure S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

10. Data from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

11. Supplementary Figure Legends from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

12. Supplementary Figure S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

13. Supplementary Figure S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

14. Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

15. Supplementary Table S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

16. Supplementary Methods from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

17. Supplementary Figure Legends from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

18. Supplementary Table S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

19. Supplementary Figure S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

20. Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

21. Abstract LB521: Antitumor activity of potent RAF inhibitors in solid tumors with activated RAS-RAF axis

22. Abstract P2-13-15: VRN101396, a brain-permeable HER2 inhibitor, shows the anti-tumor activity in preclinical HER2-positive cancer models

23. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

24. Abstract P234: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer

26. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Catalog

Books, media, physical & digital resources